Invention Grant
- Patent Title: Acylated glucagon analogue
-
Application No.: US16410736Application Date: 2019-05-13
-
Publication No.: US11274136B2Publication Date: 2022-03-15
- Inventor: Ditte Riber , Jakob Lind Tolborg , Dieter Wolfgang Hamprecht , Leo Thomas
- Applicant: Zealand Pharma A/S
- Applicant Address: DK Glostrup
- Assignee: Zealand Pharma A/S
- Current Assignee: Zealand Pharma A/S
- Current Assignee Address: DK Glostrup
- Agency: Clark & Elbing LLP
- Priority: EP15163903 20150416
- Main IPC: C07K14/605
- IPC: C07K14/605 ; A61K38/22 ; A61K38/28 ; A61K45/06 ; A61K31/135 ; A61K31/137 ; A61K31/155 ; A61K31/365 ; A61K31/64 ; A61K31/7048 ; A61K38/26
Abstract:
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Public/Granted literature
- US20200087372A1 ACYLATED GLUCAGON ANALOGUE Public/Granted day:2020-03-19
Information query
